The DOI matches its Crossref record.
Overuse of proton pump inhibitors
Open accessAbstract
BACKGROUND: There have been concerns raised about the potential adverse effects of proton pump inhibitors, especially with long-term use. In particular, their potent action can suppress the features and delay the diagnosis of gastric cancer, while prolonged exposure may hasten the development of gastric carcinoids. AIM: To examine the use of proton pump inhibitors in patients at the major teaching hospital in Tasmania, Australia, principally to determine the appropriateness of the therapy according to published guidelines. METHODS: A retrospective review of the medical records of all patients prescribed any of the proton pump inhibitors at the hospital over a 7-month period, was performed. An extensive range of demographic and clinical variables was recorded for each patient. The patients were also asked a series of questions during their hospitalization to extract some of the relevant information - in particular, if and when they had undergone endoscopy. RESULTS: The 200 patients (52% males) had a mean age of 69 +/- 16.4 years. The most common indications for using proton pump inhibitors were acute gastrointestinal bleeding (20.9%), severe refractory ulcerating oesophagitis (17.3%), mild/moderate oesophageal reflux (17.3%) and refractory peptic ulcer (11.7%). A large number of patients were using a proton pump inhibitor for 'other' indications (39.6%). The prescribing of proton pump inhibitors satisfied the approved indications, as outlined in the Australian Schedule of Pharmaceutical Benefits, in only 37.1% of cases. Endoscopy had been performed in 54.1% of patients prior to commencing therapy with a proton pump inhibitor and within the next 7 days in another 12.8% of patients. Only 59% of patients had previously been treated with an H2-receptor antagonist before commencing therapy with a proton pump inhibitor. Even worse, only 58.5% of patients had used an H2-receptor antagonist before a proton pump inhibitor for mild/moderate oesophagitis. The median duration of proton pump inhibitor therapy for patients admitted to the hospital and already receiving one of the drugs was 450 days. Over half of the patients were being concurrently treated with other drugs which are known to cause or exacerbate gastro-oesophageal disease, and 18% were smokers. CONCLUSION: Whereas the proton pump inhibitors are undoubtedly effective agents, studies of their prescribing in practice consistently suggest over-use prior to endoscopy, use in patients who do not fit the approved criteria, and prescribing for indications in which 'less powerful' agents should have been sufficiently effective for the patient's symptoms. This poses economic and safety concerns, particularly in light of the suggestion that these drugs could delay the diagnosis of gastric cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Overprescribing proton pump inhibitors
Forgacs, I., & Loganayagam, A. (2008) · BMJ · doi:10.1136/bmj.39406.449456.be · Cited by 553
Patient Barriers to and Enablers of Deprescribing: a Systematic Review
Reeve, E., To, J., Hendrix, I., Shakib, S., Roberts, M. S., & Wiese, M. D. (2013) · Drugs & Aging · doi:10.1007/s40266-013-0106-8 · Cited by 536
Reimer, C., Søndergaard, B., Hilsted, L., & Bytzer, P. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.03.058 · Cited by 356
The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal
Savarino, V., Dulbecco, P., de Bortoli, N., Ottonello, A., & Savarino, E. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2016.10.007 · Cited by 270
McDonald, E. G., Milligan, J., Frenette, C., & Lee, T. C. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.42 · Cited by 216
Metadata
- Authors
- Naunton, M., Peterson, G. M., & Bleasel, M. D.
- Venue
- Journal of Clinical Pharmacy and Therapeutics
- Publisher
- Hindawi Limited
- Published
- 2000-10
- Volume
- 25
- Issue
- 5
- Pages
- 333-340
- ISSN
- 0269-4727 (ISSN-L)
- 1365-2710
- OpenAlex
- W2088550873
- Cited by
- 183
- References
- 0
- FWCI
- 1.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Overuse of proton pump inhibitors. https://app.cochat.ai/papers/10.1046/j.1365-2710.2000.00312.x
- The paper
- Naunton, M., Peterson, G. M., & Bleasel, M. D. (2000). Overuse of proton pump inhibitors. Journal of Clinical Pharmacy and Therapeutics. https://doi.org/10.1046/j.1365-2710.2000.00312.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.